·PIB·15 marks·250–350 wordsPolityS&T

What is the One Health approach? Evaluate India's regulatory and policy response to AMR against its international commitments.

New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →
In this answer
  1. One Health: meaning
  2. India's international commitments
  3. Strengths of India's response
  4. Gaps

Antimicrobial resistance (AMR) happens when microbes stop responding to the drugs meant to kill them. WHO linked it to about 4.71 million deaths in 2021 [3]. India has committed to fighting AMR through One Health [1]. Its regulatory response is improving, but it still does not fully meet those commitments.

One Health: meaning

  • One Health treats human, animal, plant and environmental health as one connected system. Resistant microbes move between hospitals, farms, food and water.
  • The UNGA Political Declaration (2024) applies this across human health, animal health, agriculture and the environment. The Quadripartite coordinates follow-up [2].

India's international commitments

  • The G20 New Delhi Leaders' Declaration stressed tackling AMR through One Health [1].
  • Under the UNGA declaration, countries aim to cut bacterial AMR deaths by 10% by 2030. They are to have multisectoral national action plans by 2030 and report surveillance data through GLASS [2].

Strengths of India's response

  • Draft G.S.R. 983(E) would put antimicrobials in the "New Drug" definition of the NDCT Rules, 2019. A manufacturer would then need Central Licensing Authority (CLA) permission before the State Licensing Authority (SLA) licence [1].
  • It requires bioavailability/bioequivalence (BA/BE) and stability studies. These stop substandard antibiotics from under-dosing patients, which helps resistance develop [1].
  • The rule was issued as a draft with a 30-day public consultation before it is finalised [1].

Gaps

  • Enforcement record: fixed-dose combinations (FDCs) already needed central approval as new drugs. Even so, SLAs licensed many without it, and a Kokate Committee review and bans of hundreds of FDCs followed [4].
  • Regulator capacity: a 2012 parliamentary committee found 31 drugs approved without Indian clinical trials [5]. A central gate is only as strong as CDSCO's staff.
  • Only a licensing-stage check: WHO puts the failure rate for medical products in low- and middle-income countries at 10.5%, with antibiotics among the products most often reported [6]. This calls for post-market testing, which the draft does not cover.
  • Human-only focus: the draft regulates human medicines. Animal and environmental use, a core part of One Health, is not covered.

Verdict The draft shows that India is serious about drug quality, but it covers only one part of the One Health agenda. Way forward: notify the rule, add CDSCO staff, run targeted market testing of antimicrobials, and widen controls to veterinary use and pharmaceutical effluents. Together these would put India on track for the 2030 UNGA targets and SDG 3.

Sources

  1. 1PIB: Union Health Ministry draft amendment to NDCT Rules, 2019 to bring antimicrobials under central oversight (G.S.R. 983(E))(exact release page not verified, so the link goes to the PIB site): CLA→SLA sequence, BA/BE and stability studies, 30-day consultation, G20 One Health commitment
  2. 2UN Meetings Coverage, GA/12642: General Assembly Adopts Political Declaration on Antimicrobial Resistance (2024): multisectoral scope, Quadripartite mandate, 10% death-reduction target, national action plans and surveillance by 2030
  3. 3WHO, WHA78 Director-General report A78/8(exact report page not verified, so the link goes to the WHO site): 4.71 million AMR-associated deaths in 2021
  4. 4PIB: Prohibition and restriction of manufacture, sale and distribution of FDCs: SLAs licensing FDCs without DCGI approval, Kokate Committee, FDC bans
  5. 5PRS Legislative Research: Lapses in the process of drug approval in India: 2012 Standing Committee findings on CDSCO approvals without Indian trials
  6. 6WHO: 1 in 10 medical products in developing countries is substandard or falsified (2017): 10.5% failure rate, antibiotics among the products most often reported
Practice
7 questions on this item
Check the answer for each question, or reveal all at once.
Practice MCQs →

More from this note

More on Polity